Mirati Therapeutics Inc. (MRTX)
Company Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States.
The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development.
It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib.
Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
| Country | United States |
| IPO Date | Jul 15, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 587 |
| CEO | Dr. Charles M. Baum M.D., Ph.D. |
Contact Details
Address: 3545 Cray Court San Diego, California United States | |
| Website | https://www.mirati.com |
Stock Details
| Ticker Symbol | MRTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001576263 |
| CUSIP Number | 60468T105 |
| ISIN Number | US60468T1051 |
| Employer ID | 46-2693615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David D. Meek | Chief Executive Officer & Director |
| John B. Moriarty Jr., J.D. | Chief Legal Officer & Corporate Secretary |
| Laurie D. Stelzer | Chief Financial Officer |
| Michael E. Paolucci | Chief People Officer |
| Reena R. Desai | Chief Legal Officer & Corporation Sec. |
| Benjamin J. Hickey M.B.A. | Chief Commercial Officer |
| Betsy Gelfand C.P.A. | Chief Accounting Officer, Principal Accounting Officer & Vice President of Fin. |
| Betsy Gelfand CPA | Chief Accounting Officer, Principal Accounting Officer & Vice President of Finance |
| Dr. Alan Bart Sandler M.D. | Executive Vice President & Chief Medical Officer |
| Dr. James G. Christensen Ph.D. | Executive Vice President & Chief Scientific Officer |
| Dr. Kelly Covello Ph.D. | Vice President & Head of Medical Affairs |
| Laurie D. Stelzer M.B.A. | Consultant |
| Peter Lee | Chief Compliance Officer |
| Ryan Asay | Vice President & Head of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 09, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Feb 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Feb 02, 2024 | 15-12G | Filing |
| Jan 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |